LOS ANGELES, April 9, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
Mr. Eric Curtis, Advisor to the
Chairman and Chief Executive Officer, along with Dr. Felix Kratz, Vice President of Drug Discovery,
will host an investor conference call and webcast beginning at
11:00 a.m. Eastern Time (10:00 a.m. Central Time / 8:00 a.m. Pacific Time) on Wednesday, April 18, 2018. Dr Kratz will discuss
the scientific data for each of the four new albumin binding ultra
high potency LADR™ drug candidates presented at the American
Association of Cancer Research (AACR) Annual Meeting in
Chicago, April 14-18, 2018. Mr. Curtis will discuss
current partnership developments with Big Pharma for the LADR™ drug
candidates, and their significant advantages over antibody-drug
conjugates.
To access the conference call, dial 844-358-6753 (U.S. and
Canada) or 216-562-0397
(international callers) and enter the conference ID number:
2798507. A live and archived webcast of the presentation will
be available in the Investor Relations section of the company's
website, www.cytrx.com, under News & Events – Events Calendar.
A replay of the call and webcast will begin approximately two hours
after the live call has ended. To access the replay, dial
855-859-2056 (U.S. and Canada) or
404-537-3406 (international callers) and enter the conference ID
number: 2798507.
The posters are:
- SUPERIOR EFFICACY OF NOVEL ALBUMIN-BINDING AURISTATIN
E-BASED DRUGS COMPARED TO AURISTATIN E IN A PANEL OF HUMAN
XENOGRAFT MODELS IN MICE.
Session Category and Title: Cancer Chemistry; Drug
Delivery
Session Date and Time: Tuesday, April 17,
2018 8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster
Section 30
Poster Board Number: 3
- STRUCTURE-ACTIVITY RELATIONSHIP STUDIES AND BIOLOGICAL
EVALUATION OF NOVEL MAYTANSINOIDS, A CLASS OF HIGHLY SELECTIVE
TUBULIN INHIBITORS.
Session Category and Title: Cancer Chemistry; Target
Based Drug Discovery
Session Date and Time: Monday, April 16,
2018; 8:00 a.m. to 12:00 p.m.
CT
Location: McCormick Place South, Exhibit Hall A, Poster
Section 30
Poster Board Number: 12
- NOVEL ALBUMIN-BINDING MAYTANSINOIDS INDUCING LONG-TERM
PARTIAL AND COMPLETE TUMOR REGRESSIONS IN SEVERAL HUMAN CANCER
XENOGRAFT MODELS IN NUDE MICE.
Session Category and Title: Cancer Chemistry; Antitumor
Agents
Session Date and Time: Monday, April 16,
2018 1:00 PM - 5:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster
Section 30
Poster Board Number: 1
Copies of the posters will be available on the CytRx website
(www.cytrx.com) under the "Investor Relations - Presentations" tab
on Tuesday, April 17, approximately
one hour following the last
presentation.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company specializing in
research and clinical development of novel anti-cancer drug
candidates that employ linker technologies to enhance the
accumulation and release of drug at the tumor. CytRx is also
rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated
Drug Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies. Aldoxorubicin, CytRx's most advanced
drug conjugate, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc.
About AACR
AACR is the oldest and largest scientific organization in the
world focused on every aspect of high-quality, innovative cancer
research. Its reputation for scientific breadth and excellence
attract the premier researchers in the field. The organization's
programs and services foster the exchange of knowledge and new
ideas among scientists dedicated to cancer research, provide
training opportunities for the next generation of cancer
researchers, and increase public understanding of cancer.
Presentations at the AACR Annual Meeting will cover the latest
basic, translational, clinical, and prevention-focused research in
the field, including important areas such as early detection,
cancer interception, and survivorship in all populations.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; our ability to develop new ultra-high potency drug
candidates based on our LADR™ technology platform; and
other risks and uncertainties described in the most recent annual
and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report. All forward-looking statements
are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll (212)
600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-to-present-breakthrough-data-on-albumin-binding-ultra-high-potency-ladr-drug-candidates-at-the-aacr-2018-conference-300625888.html
SOURCE CytRx Corporation